Claims

Regulatory oversight by bodies such as the US FDA is presented as critical for fostering trust in AI among clinicians and patients

Claim · All claims
Evidence · 1 study · review r2 · q2
Currency · newest study 2025 · not yet checked against its sources · not reviewed by a person · recheck by 2030: baselines and conditions change

Subclaims

Reading the evidence codes

q is the design tier, i the impact, n the sample, and the kind with its r the rigour judged within that kind: what each code means.

This claim: no standardized effect is recorded in observations/ for it yet, so no benchmark reading is possible.

q2 i? The review argues that regulatory oversight, such as FDA approval of specific AI tools for medical applications, fosters trust and mitigates liability concerns. → Gazquez-Garcia J 2025

Evidence

Gazquez-Garcia J 2025

Gazquez-Garcia J, Sánchez-Bocanegra CL, Sevillano JL. (2025). AI in the Health Sector: Systematic Review of Key Skills for Future Health Professionals. JMIR Medical Education. https://doi.org/10.2196/58161

q2 · i? · review · r2

The review's interpretive discussion (authors' argument, not a tested result): FDA approval of specific AI tools provides assurance that technologies meet safety and legal standards, fostering trust among clinicians and patients.

"Regulatory bodies such as the US Food and Drug Administration have already approved specific AI tools for medical applications [38], providing a level of assurance that these technologies meet rigorous safety and legal standards."

Discussion

Page metadata
Field Value
status review
generated by process:wiki-ingest on 2026-10-31
trust unverified — no one has confirmed this page's content

Frontmatter is the page's machine-readable record — see the Schema & Guide.